By integrating both a discovery and an independent validation cohort, our study aims to directly address key knowledge gaps pertaining to peripheral pre-symptomatic disease states and to establish a robust framework for advancing peripheral TDP-43 pathology as a clinically meaningful biomarker in ALS. This evidence concerns the gene TARDBP and amyotrophic lateral sclerosis.